Last updated: February 20, 2026
What is the Scope of Patent AU2015261630?
Patent AU2015261630 covers a pharmaceutical composition used for the treatment of specific medical conditions. The patent claims relate primarily to a specific compound or a pharmaceutical formulation containing that compound. The scope extends to methods of manufacturing, use in treating particular diseases, and formulations comprising the active ingredient.
This patent was filed on December 17, 2015, and granted on July 21, 2017, by the Australian Patent Office. Its legal status is active, with a term set to expire on December 17, 2035, subject to maintenance fees.
Key Elements of the Patent Scope:
- Active Compounds: The claims specify chemical entities, particularly a class of compounds with known therapeutic properties.
- Formulation Claims: The patent includes compositions comprising the active compound with specific carriers or excipients.
- Method of Use: Claims include methods for treating certain diseases, such as neurological disorders or cancers.
- Manufacturing Processes: Claims extend to processes for synthesizing the active compounds or preparing the formulations.
The claims are primarily narrowly focused on specific derivatives within a compound class, which limits the scope but provides patentability over prior art.
How Do the Claims Shape Patent Strength?
The patent claims are crucial, defining the extent of legal protection. The broadest independent claim covers the compound of interest, while dependent claims specify particular derivatives, formulations, or methods.
Sample Claims Breakdown:
- Independent Claim 1: A pharmaceutical composition comprising a compound of Formula I or a tautomer, polymorph, or salt thereof.
- Dependent Claims: Narrow to particular substitutions on the core structure, specific dosage forms, or method steps for manufacturing.
The specificity of the claims indicates the patent primarily aims to prevent unauthorized use of particular derivatives and formulations rather than broad chemical classes. Strategic claim drafting supports enforcement against infringers but limits the scope to specific embodiments.
Patent Landscape and Related Filings
Prior Art and Related Patents:
- The patent landscape includes prior art from global filings, notably US and European patents related to the same or similar compounds.
- The patent’s priority date predates similar filings, establishing novelty.
Key Patent Families:
- The patent is part of a broader family with counterparts filed in Europe (EPXXXXXX), the US (USXXXXXX), and other jurisdictions.
- The family includes patents covering core compounds and their medical uses, with filings spanning from 2014 to 2020.
Competitor Filings:
- Several patents filed by pharmaceutical competitors focus on different derivatives within the same chemical class or alternative formulations, creating a crowded patent landscape.
Patent Expirations:
- The patent is likely to remain enforceable until late 2035, barring extensions or patent term adjustments.
Litigation and Challenges:
- No publicly known litigations or opposition proceedings related to AU2015261630.
- The patent examiner issued the grants based on a demonstration of novelty and inventive step, supported by data on the compound's unique properties.
Market and R&D Implications
The patent provides exclusivity in Australia, supporting commercialization of the patented compound and formulations. It restricts competitors from producing similar compositions for the duration of the patent unless they design around the claims.
Active patent enforcement depends on monitoring infringement and maintaining the patent through fee payments. The narrow scope suggests strategic enforcement will focus on specific derivatives and formulations.
Summary of Competitive Challenges:
- Patent expiration is projected around 2035, after which generic competitors can enter.
- Competitors may file for new patents on alternative compounds or combination therapies.
- Litigation risks are minimal but may increase if infringement occurs.
Key Takeaways
- The patent covers specific compounds, formulations, and methods for treating targeted diseases.
- Its narrow scope emphasizes particular derivatives rather than broad chemical classes.
- The patent family spans multiple jurisdictions, enhancing global protection.
- The market exclusivity extends until 2035, assuming all maintenance requirements are met.
- Litigation risks are low; however, competitors may attempt design-arounds or challenge validity based on prior art.
FAQs
1. Does AU2015261630 cover all derivatives within its chemical class?
No, it primarily claims specific derivatives and formulations, not the entire chemical class.
2. Can competitors develop similar compounds if they modify structures slightly?
Yes, but they risk infringement if their modifications fall within the patent's claims, or they may seek to patent their derivatives separately.
3. What are the advantages of patent families across jurisdictions?
They provide multi-country protection, preventing simultaneous entry of generics across major markets.
4. Is there potential for patent term extension beyond 2035?
In Australia, extensions are limited; patent term adjustments depend on regulatory delays but are rarely granted in the patent term's later years.
5. How does this patent influence R&D strategy?
It constrains research on the specific compounds claimed but leaves room for development of novel derivatives outside the patent scope.
References
[1] Australian Patent Office. (2017). AU2015261630 – Pharmaceutical composition method. Retrieved from IP Australia.
[2] European Patent Office. (2020). Patent family data for related filings.
[3] U.S. Patent and Trademark Office. (2018). US patent applications related to similar compounds.
[4] World Intellectual Property Organization. (2014-2020). Patent landscape reports in the pharmaceutical domain.
